US HB741 | 2011-2012 | 112th Congress
Status
Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on February 16 2011 - 25% progression, died in committee
Action: 2011-02-28 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 16 2011 - 25% progression, died in committee
Action: 2011-02-28 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the exclusivity period granted to the generic manufacturer.
Title
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Sponsors
| Rep. Jo Emerson [R-MO] |
History
| Date | Chamber | Action |
|---|---|---|
| 2011-02-28 | House | Referred to the Subcommittee on Health. |
| 2011-02-16 | House | Referred to the House Committee on Energy and Commerce. |
Same As/Similar To
SB373 (Related) 2011-02-16 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/112th-congress/house-bill/741/all-info |
| Text | https://www.congress.gov/112/bills/hr741/BILLS-112hr741ih.pdf |
